The clock is ticking—and “generic” isn’t a single moment. It’s a timeline.
If you’re building a true generic entry strategy, the biggest risk isn’t whether your product can win scientifically—it’s whether it can win on time. In today’s regulatory env…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

The Patent War Isn’t a Theory—It’s a Cash-Flow Strategy. Here’s How “Pay-for-Delay” Decides Who Gets Paid (and Who Gets Blocked).
In pharma, the moment a drug is approved is only the beginning of the real competition: the race to control the calendar.
…

Consumers Don’t Always Pay More for “Brand.” They Pay for Certainty.
In the pharmaceutical market, the word generic can sound like a promise: lower cost, same medicine, no trade-offs. And yet, many patients still end up paying a “trust premium”—somet…

AI is already “reading” your drug—before your competitors do. Here’s what that means for IP, pricing, and strategy.
In pharma, we’ve spent years building defensible advantages: patents, exclusivities, manufacturing know-how, payer relationships, and cl…

Most pharma teams don’t lose because they lack data. They lose because they don’t close the intelligence gap.
In patent strategy, the difference between “we’re monitoring” and “we’re winning” is often one thing: how quickly and how completely you trans…

The biologics patent war isn’t a single fight—it’s two systems moving in sync.
If you’ve ever wondered why the biologics landscape feels like it’s always on the verge of litigation, settlement, and surprise “wins,” the answer is that the battlefield …

Most teams don’t lose to competitors because they’re slower—they lose because they’re blind.
In pharma, “timing” isn’t a buzzword. It’s the difference between launching with pricing power and launching into a crowded, discounted market. And yet, many b…

After the patent falls, the real fight begins.
Most people think the end of a drug’s exclusivity is the end of the story. In reality, it’s the opening move in a high-stakes chess match—one where timing, regulatory strategy, and litigation posture can…

AI is your drug’s new KOL—and you’re not tracking it.
For years, pharma has treated “key opinion leaders” as people: the professors, trialists, and guideline-shapers whose names show up in slide decks and speaker bureaus. But the center of gravity is s…